CTA 30X
Alternative Names: CTA30X; CTA30X cell injection; CTA30X UCAR-TLatest Information Update: 28 Sep 2024
At a glance
- Originator Nanjing Bioheng Biotech
- Developer Nanjing Bioheng Biotech; Zhejiang University
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (IV, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (IV, Injection)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in China (IV, Injection)